Efficacy of Aripiprazole in patients with chronic schizophrenia.

Phase 4

• Conditions: chronic schizophrenia

• Registration Number: JPRN-UMIN000006550
• Lead Sponsor: Gifu University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-10-16
• Study Completion: 2014-09-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patient whose a current psychosis is unstable. 2)Patients who are in coma. 3)Patients who are under strong influence of central-nervous depressants,such as barbiturates /anaesthetics. 4)Patients who have received Vegetamin(r). 5)Patients have received epinephrine. 6)Patients who are under influence of neuroactive action by stimulants,alcohol. 7)Patients who have a history of hypersensitivity reaction to aripiprazole. 8)Female patients who are pregnant or may have become pregnant. 9)Patients who are judged inappropriate by investigator. 10)Patients with intellectual disability concomitantly. 11)Patients with dementia 12)patients with personality disorder concomitantly.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Achievement rate of reduction (less or equal two antipsychotics,less or equal 1000mg/day at CP equivalent, and over 20% reduction), Extrapyramidal symptoms (DIEPSS)

Secondary Outcome Measures

Name	Time	Method
Psychosis (Positive and Negative Syndrome Scale: PANSS), Cognitive function (BACS-J), Preference of medicine (POM)